During our preliminary molecular survey of the cystic fibrosis (CF) AF508 mutation in 18 patients selected by positive sweat tests, we found one patient with agenesis of the cochlea (Mondini's syndrome), several bouts of dehydration, and absence of pulmonary digestive complications. This 12 year old girl was born to unrelated, non-Caucasian parents and a heterozygous AF508/ non-AF508 genotype was found in her lymphocytes. In our study only 33.5% of patients were found to be homozygous for the classical CF mutation, 11.8% were heterozygous, and the remaining majority of patients were not carriers of the AF508 mutation. As expected in our mixed non-Caucasian population, several other combinations of CF mutations may be found in a rather different distribution compared to European countries. Recently, Raskin et all showed that 46% of their patients in a more homogeneous racial region of Brazil were homozygous for the AF508 mutation. As a consequence, minor and uncommon clinical presentations of CF would be expected to occur in our population. Our patient with sensorineural deafness as a result of agenesis of the cochlea could have resulted from a similar mechanism to, for example, congenital agenesis of the vas deferens in infertile males, in whom CF mutations have recently been reported.2 It is possible in our population that CF patients may be found more frequently in different clinics seeking medical attention for other reasons than those expected in classical CF patients.
During our preliminary molecular survey of the cystic fibrosis (CF) AF508 mutation in 18 patients selected by positive sweat tests, we found one patient with agenesis of the cochlea (Mondini's syndrome), several bouts of dehydration, and absence of pulmonary digestive complications. This 12 year old girl was born to unrelated, non-Caucasian parents and a heterozygous AF508/ non-AF508 genotype was found in her lymphocytes. In our study only 33.5% of patients were found to be homozygous for the classical CF mutation, 11.8% were heterozygous, and the remaining majority of patients were not carriers of the AF508 mutation. As expected in our mixed non-Caucasian population, several other combinations of CF mutations may be found in a rather different distribution compared to European Professor Brock favours non-disclosure couple screening over two step screening on economic grounds, as two step screening requires satisfactory counselling of carriers and causes maternal anxiety until a partner's result is available. Nevertheless, we believe that carrier information may be of benefit to those screened, giving information for future pregnancies with different partners and allowing relatives to be informed.'2 Unless careful research can show that those screened and their families do not benefit from information provided by good counselling of carriers, we believe that disclosure of results is an ethical necessity. We accept that counselling of carriers requires resources, but, especially as the population becomes more aware of genetic risks, it allows targeting of genetic information to those at high risk. Disclosure couple screening would allow carrier information to be of benefit, but the anxiety associated with two step screening might be decreased as partners results would be immediately available.3 The Edinburgh finding of no difference in uptake of the two forms of screening mirrors the results of our own randomised trial of couple v two step screening (91% uptake of two step screening v 89% for couple screening4). Once the full results of our psychological and economic evaluation are available we will be able to comment further on the suitability of different approaches to screening.
Although couple screening avoids the need for counselling of detected carriers, proper counselling and explanation is still required to allow couples to give informed consent to carrier testing. Failure to obtain truly informed consent to a screening test is unethical and exposes a health authority to risk of litigation.' Carrier testing must be explained by staff who fully understand its advantages, limitations, and drawbacks.
Severe cystic fibrosis in a child homozygous for the G542 nonsense mutation in the CFTR gene Several homozygous nonsense mutations in the CFTR gene (S1255X/G542X, W1316X/ R553X, G542X/G542X, R553X/R553X, and RI 162X/R1 162X) have been reported.'-These patients were mildly affected, suggesting that the nonsense mutation alone may lead to mild expression of the disease, particularly mild lung symptoms. 1-6 Some hypotheses have been proposed to explain the minor pulmonary involvement in comparison to the severe pancreatic dysfunction in these patients: (1) the possible presence of tissue specific RNA splicing minimising the effect of the nonsense mutation, (2) residual function of the truncated protein in certain tissues, such as lung, and (3) the partial substitution of the missing function by alternative pathways occurring only in pulmonary epithelium.4 None of these explanations has yet been substantiated. These papers suggested that the lack of CFTR protein in airway cells may be less damaging than the presence of a structurally abnormal protein. This is in contrast to many monogenic diseases, such as haemophilia, in which the presence of nonsense mutations is frequently associated with a more severe clinical picture when compared to that associated with missense mutations.7 In these cases, nonsense mutations cause severe illness because premature termination of translation creates truncated proteins, which are usually non-functional or unstable.
We present the clinical and molecular findings in a child homozygous for G542X with severe pancreatic and pulmonary disease.
This Turkish boy was born at term (birth weight 3200 g) and presented with meconium ileus, successfully treated with enemas. Cystic fibrosis (CF) was confirmed by two positive sweat tests at 3 months and conventional treatment for CF was started. Because of an early episode of pulmonary infection, he was admitted to hospital at 5 months; Haemophilus influenzae was first isolated from sputum cultures, then Pseudomonas aeruginosa and Klebsiella. After 15 days of IV treatment with cephalosporins and aminosides, followed by aerosol colimycin, his pulmonary state improved. Abundant stools were passed. Under treatment with pancreatic enzymes, the clinical course improved but nutritional indices remain low. Lung function as expressed by blood gas values was abnormal (pO2 59 mm Hg and pCO2 33 mm Hg in the absence of pulmonary infection) and oral antibiotics were necessary after discharge.
A homozygous G542X mutation was found by DGGE and identified by exon 11
Letters to the Editor amplification using a modified primer on the 5' side of codon 542 and subsequent digestion with BstNI.5 The mutation (G-'T at 1756) was characterised by direct sequencing using the Sequenase USB kit by standard methods. G542 is a nonsense mutation in which a glycine at codon 542 is replaced with a stop codon G542X in the cystic fibrosis transmembrane conductance regulator gene.' This boy has a severe lung involvement, meconium ileus, and pancreatic insufficiency, as indicated by the high degree of steatorrhoea. The G542 nonsense mutation was associated with a severe clinical phenotype in the neonatal period.
This case shows that, in contrast to earlier reports, the G542 nonsense mutation alone, which truncates the gene product to 37% of its length, may lead to severe cystic fibrosis. The proband was originally seen when she was 21 years of age. At that time the coarse facial features and loose skin had suggested a diagnosis of cutis laxa (fig 1) . A subsequent skin biopsy showed that the elastic fibres were normal on histological examination, but there was a relative deficiency of well formed collagen fibres. Her development has continued to be considerably delayed. She walked at 5 years and has received special education. Feeding has remained a problem, although no anatomical or physiological abnormality has been specifically identified. She was treated with growth hormone from 4 years of age and at 10 years her height is 1185 cm (<3rd centile). She has always been relatively macrocephalic (head circumference has been on the 25th centile) and her anterior fontanelle was late in closing. Her facial features have been relatively coarse with a flat nasal bridge, hypertelorism, downward slanting palpebral fissures, a short neck, and a barrel shaped chest. She has a moderate lumbothoracic scoliosis with limitation of movement at the knees and elbows. There is pes planus with a tendency to walk with the feet in an everted position.
At 6 years of age she developed nasal warts which have tended to recur in spite of aggressive treatment using cryosurgery. She has no warts elsewhere and she has had no adverse reaction to other viral infections. Her routine immunological parameters are normal. Although she is of West Indian origin, her skin is considerably darker than the other members of her family especially over the dorsum of her hands. Hyperpigmentation has also been reported in 
